We're excited to share that BioWorld, a globally recognized biotech and pharmaceutical news outlet, recently featured an exclusive interview with Dr. Jeng Her, CEO of AP Biosciences.
“When I first went to the United States 35 years ago, I had my first cultural shock, and when I came back to Taiwan 12 years ago, I had my second cultural shock”
That's how Dr. Jeng Her described his entrepreneurial journey in the interview. Facing the challenges of Taiwan's relatively small biotech ecosystem, where both talent and funding can be difficult to secure, AP Biosciences has chosen to move forward one solid step at a time.
This perseverance is reflected in the development of the company’s bispecific antibody, AP402. Designed for patients who have HER2-targeted therapy resistance, AP402 targets p95HER2, a truncated form of the HER2 protein known to be associated with resistance to current HER2-targeted therapy.
AP402 is currently the first-in-class bispecific antibody in clinical development specifically targeting p95HER2. It conditionally activates CD137 on T cells, stimulating an immune response against cancer cells without increasing toxicity. The drug is currently undergoing a Phase I/II clinical trial in Australia.
Whether in scientific research or on the entrepreneurial path, AP Biosciences tackles challenges with innovative thinking and agile strategy, committed to creating competitive therapies with long-term value.
📖 Read the full article:
AP Bio heads to phase I/II with bispecific for HER2-resistant tumors
